Measurement of neuronal morphological changes is an important tool in the search for drugs that may impact neuronal degenerative diseases, such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS), and others. Conversely, compounds that exhibit neurotoxicity need to be avoided. The ability to assess neurotoxicity in early stage drug development would aid in preventing unexpected adverse effects during clinical studies. One important endpoint for assessing neurotoxicity is neurite outgrowth, such as neurite number and length. Scoring of neurite morphological features has traditionally been done manually. These methods are usually labor intensive, time consuming and subject to bias. Automated detection and analysis of neurite outgrowth is an advantageous tool for screening compounds in early drug discovery.
Neurite OutgrOwth AssAy
The neurite outgrowth assay assesses four endpoints which were measured simultaneously in the same cell population. The endpoints, definitions and principles are described in the following 
PrOtOCOl
PC12 cells (from ATCC) are seeded in 96-well collagen IV-coated plates (~3,000 cells/well). Cells are allowed to attach overnight and then treated with a test compound and 50 ng/mL NGF, in triplicate, in assay medium containing 1% HS and 0.5% FBS. The final DMSO concentration is 0.1% (which is at the highest DMSO tolerance level for this assay). After incubation at 37°C/5% CO2 for 6 days, the cells are fixed and then stained with Hoechst and βIII-tubulin antibody.
After the staining process, the plates are scanned with an automated fluorescent microscope-conjugated camera (ThermoFisher Cellomics ArrayScan 4.5). Cellomics image-analysis software is used to detect nuclei, cell bodies, and neurites in PC12 cells.
Negative controls are wells that are treated with only vehicle (0.1% DMSO, no NGF). Positive controls are wells that are co-treated with vehicle (0.1% DMSO) and 50 ng/mL NGF. The neurite outgrowth assay requires only about 1 mg of compound to test at the top concentration of 100 µM (assuming a MW of approximately 500).
turNArOuND tiMe \
The results are delivered within 3 weeks upon receipt of the compounds at the Cerep testing site. Data are available online as soon as they are validated.
ObjeCtive AND CONsisteNt sCOriNg \ Automated scoring bypasses the subjectivity and inconsistency of manual scoring.
Neurite OutgrOwth AssAy COMPOuND trAiNiNg set
A set of training compounds were tested in the neurite outgrowth assay in order to validate this assay at Cerep. IC 50 values were calculated for the compounds that inhibited neurite outgrowth. For the compounds that enhance neurite outgrowth or have no effect on neurite outgrowth, the % effect relative to NGF treated cells were listed at the highest non-cytotoxic concentrations or the highest tested concentrations. Our assay showed a high sensitivity by correctly predicting the reported inhibitory effects of compounds k-252a, retinoic acid, SU6656 and U0126; as well as the known enhancement effects of compounds Y27632, fasudil and dopamine on neurite outgrowth (1-3).
COMPOuNDs thAt iNhibit
The observation that tetrodotoxin has no eftfect on neurite outgrowth is consistent with a previous study (4). PC12 cells are also known for not having a functional target for picrotoxin, a potent neurotoxin (5). Indeed, the neurite outgrowth in PC12 cells is not affected by picrotoxin treatment in our assay. These results demonstrate the specificity of our assay.
Overall, our assay is a rapid and reliable tool for assessing neurite outgrowth in PC12 cells. This assay can be useful in both drug discovery programs for identifying neuronal protective compounds and in early drug development for potential neurotoxicity screening.
